MajorProkinetic, peripheral dopamine D2 receptor antagonist×Class Ic antiarrhythmic with beta-blocking activity
Updated · Methodology
Mechanism
Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day and with QT-prolonging drugs (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Propafenone, a class IC antiarrhythmic with weak beta-blocking activity, prolongs the PR interval and widens the QRS complex. According to the US label, it may also prolong the QT interval, but QRS widening makes QT changes difficult to interpret (propafenone SmPC, AEMPS, and label, US Food and Drug Administration, FDA). The Spanish domperidone SmPC explains that combinations with QT-prolonging drugs are contraindicated because pharmacodynamic or pharmacokinetic interactions raise the risk of QT prolongation. It also names a slow heart rate as a factor that increases the risk of arrhythmia (AEMPS), and propafenone can slow the heart rate (propafenone SmPC, AEMPS). Propafenone may raise the levels of drugs that CYP2D6 metabolises. CYP2D6 is not among the enzymes that metabolise domperidone: these are mainly CYP3A4, plus CYP1A2 and CYP2E1 (propafenone and domperidone SmPCs, AEMPS). The documents give no data on how one drug changes the level of the other.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Propafenone can cause new or worse arrhythmias, including ventricular tachycardia, ventricular fibrillation and torsade de pointes, as well as heart block and a slow heart rate (propafenone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and label, US Food and Drug Administration, FDA). With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone SmPC, AEMPS). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
Avoid the combination. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with QT-prolonging drugs, and propafenone is not among the examples (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish propafenone SmPC mentions QT prolongation only as a reason to lower the dose. The US label says propafenone may prolong QT, but QRS widening makes this hard to assess (propafenone SmPC, AEMPS, and label, US Food and Drug Administration, FDA). For this reason, the editors do not classify the combination as contraindicated. The US propafenone label says to avoid other QT-prolonging drugs because such combinations have not been extensively studied (propafenone FDA label). Domperidone's own Spanish SmPC links it to QT prolongation (AEMPS). Domperidone is contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure. Use it with caution with drugs that cause bradycardia (domperidone SmPC, AEMPS). Propafenone is contraindicated in severe symptomatic bradycardia, marked electrolyte imbalance and uncontrolled congestive heart failure with a left ventricular ejection fraction below 35% (propafenone SmPC, AEMPS). Record an electrocardiogram (ECG) before and during propafenone treatment. If the QRS complex or the heart-rate-corrected QT interval (QTc) lengthens, or second- or third-degree atrioventricular block appears, lower the dose or interrupt treatment until the ECG returns to normal (propafenone SmPC, AEMPS). If domperidone and propafenone have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Propafenona (nº registro 55538), sección 4.5 (2019)– AEMPS, CIMA, nº registro 55538 (Rytmonorm 150 mg comprimidos recubiertos), revisión 03/2019, secciones 4.2, 4.3, 4.4, 4.5, 4.8 y 4.9
- FDA: Propafenone hydrochloride tablets (propafenone) prescribing information (2025)– FDA, DailyMed setid c65253ab-937f-4982-b841-69c2b9f9ccdb (Strides Pharma Science), revisión 09/2025 (versión 3), secciones 2, 5.1, 5.3, 5.4, 7.1, 12.2 y 12.3